Spruce Biosciences (SPRB) Other financing activities (2020 - 2025)
Spruce Biosciences (SPRB) posted quarterly Other financing activities of $25000.0 for Q4 2025, up 121.93% year-over-year from $11264.8 in Q4 2024, and up 121.93% quarter-over-quarter from -$114000.0 in Q4 2024.
Spruce Biosciences (SPRB) Other financing activities (2020 - 2025) Analysis & Trends
Spruce Biosciences (SPRB) has reported Other financing activities for 6 consecutive years, with $25000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other financing activities rose 121.93% year-over-year to $25000.0; the TTM figure through Dec 2025 stood at $25000.0 (down 62.12% YoY), while the FY2025 annual figure was $25000.0, down 62.12% from the prior year.
- Other financing activities improved to $25000.0 in Q4 2025 per SPRB's latest filing, from -$114000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $180000.0 in Q1 2024 and bottomed at -$114000.0 in Q4 2024.
- Historically, Other financing activities has averaged $19416.7 across 5 years, with a median of $21000.0 in 2021.
- Annual changes were most pronounced in 2022 — Other financing activities plunged 323.53% — and 2023, when it surged 360.53%.
- Spruce Biosciences' Other financing activities stood at -$26000.0 in 2021, then plunged by 46.15% to -$38000.0 in 2022, then sank by 139.47% to -$91000.0 in 2023, then declined by 25.27% to -$114000.0 in 2024, then soared by 121.93% to $25000.0 in 2025.
- Business Quant data shows SPRB's Other financing activities at $25000.0 in Q4 2025, -$114000.0 in Q4 2024, and $180000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 25,000.00 |
| Dec 31, 2025 | 25,000.00 |
| Dec 31, 2024 | -114,000.00 |
| Dec 31, 2024 | -114,000.00 |
| Mar 31, 2024 | 180,000.00 |
| Mar 31, 2024 | 180,000.00 |
| Dec 31, 2023 | -91,000.00 |
| Dec 31, 2023 | -91,000.00 |
| Sep 30, 2023 | 99,000.00 |
| Sep 30, 2023 | 99,000.00 |
| Sep 30, 2022 | -38,000.00 |
| Sep 30, 2022 | -38,000.00 |
| Jun 30, 2022 | 36,000.00 |
| Jun 30, 2022 | 36,000.00 |
| Mar 31, 2022 | 2,000.00 |
| Mar 31, 2022 | 2,000.00 |
| Dec 31, 2021 | -26,000.00 |
| Dec 31, 2021 | -26,000.00 |
| Sep 30, 2021 | 17,000.00 |
| Sep 30, 2021 | 17,000.00 |